Oracle stock falls after report reveals thin margins in AI cloud business
ORANGE, Calif. - Alignment Healthcare, Inc. (NASDAQ: ALHC), a provider of Medicare Advantage plans, announced the immediate resignation of two members of its Board of Directors, Thomas (TJ) Carella and Jeffrey Margolis. While stepping down from the board, Margolis will transition to an advisory role within the company.
Joseph Konowiecki, chairman of the Alignment Board, expressed gratitude for both Carella and Margolis' contributions to the company's growth and their insights into the evolving healthcare sector. John Kao, founder, CEO, and board member of Alignment Healthcare, also acknowledged the significant impact both individuals have had on the company's trajectory, particularly in serving the healthcare needs of seniors.
Carella, who joined the Board in 2017, commented on his commitment to the company's approach to high-quality, cost-effective care with superior patient outcomes. He remains confident in Alignment's future influence in the healthcare industry. Margolis, a board member since 2014, reflected on his decade-long collaboration with Kao, highlighting the company's distinct vision for senior health and its potential to outpace competitors.
The departures of Carella and Margolis are not due to any disagreements with the company's operations, policies, or practices.
Alignment Healthcare champions a new direction in senior care, offering Medicare Advantage plans that prioritize coordinated care, 24/7 concierge services, and innovative technology. The company operates in 53 counties across six states, emphasizing a member-first philosophy and aiming to provide high-quality, low-cost care.
This announcement is based on a press release statement and does not reflect any disagreement with company practices.
In other recent news, Alignment Healthcare has seen robust growth in the second quarter, with a 56% increase in health plan membership and a 47% rise in revenue year-over-year. This growth has led Baird, TD Cowen, and Piper Sandler to raise their stock price targets for the company. Baird raised its target from $10.00 to $11.00, highlighting the company's potential for strong performance in 2025 due to key factors such as a projected improvement in the medical loss ratio and a Star Ratings advantage in California.
TD Cowen increased its target to $10.00, following the company's second-quarter results that surpassed expectations. The firm's revised model now includes expected changes to Part D through 2025 and slightly higher EBITDA projections for the years 2024 and 2025. Similarly, Piper Sandler also raised its target to $10.00, following Alignment Healthcare's announcement of a significant second-quarter revenue beat.
These recent developments include an upward revision in year-end membership guidance by 8,000 members and a forecast of at least 20% growth in 2025. Despite the strong performance, Alignment Healthcare plans to focus on profitability and expanding its national footprint, with no plans to enter new states in 2025. With these developments, Alignment Healthcare continues to be a company of interest for investors.
InvestingPro Insights
As Alignment Healthcare, Inc. (NASDAQ: ALHC) navigates through changes in its Board of Directors, market participants are closely monitoring the company’s performance metrics and analyst forecasts. According to InvestingPro data, Alignment Healthcare currently has a market capitalization of approximately $1.65 billion. Despite a substantial revenue growth of 37.46% over the last twelve months as of Q2 2024, the company maintains a negative P/E ratio of -10.66, indicating that it is not currently profitable.
InvestingPro Tips reveal that analysts have recently revised their earnings expectations downwards for the upcoming period, signaling potential headwinds for the company's financial outlook. Moreover, Alignment Healthcare is grappling with weak gross profit margins of 10.65%, which may be a factor for investors to consider in light of the recent board reshuffle.
On a positive note, the company has experienced a strong return over the last three months, with a 22.89% price total return, and an even more impressive six-month price total return of 29.37%. Nevertheless, analysts do not anticipate Alignment Healthcare will be profitable this year, which could impact long-term investment decisions.
The company’s stock is currently trading at a high Price / Book multiple of 13.45, which may suggest that its assets are being valued at a premium in the market. This metric, alongside the fact that Alignment Healthcare does not pay a dividend to shareholders, might influence investment strategies, especially for income-focused investors.
For those interested in a deeper analysis, there are additional InvestingPro Tips available for Alignment Healthcare on InvestingPro, which can provide a more comprehensive understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.